| Next 10 |
VBLT News and Press, Vascular Biogenics Ltd.
-
Gainers: Yunhong CTI (CTIB) +51%.TimkenSteel (TMST) +42%.Frank's International (FI) +33%.Sunesis Pharmaceuticals (SNSS) +22%.EverQuote (EVER) +14%.China Southern Airlines (ZNH) +14%.The L.S. Starrett (SCX) +14%.Centrais Eletricas Brasileiras (EBR) +11%.Ardagh Group (ARD) +11%.Vascul...
-
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed (PAVM) -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics (ONTX) -15%, elect...
-
ReTo Eco-Solutions (RETO) +132%.ATIF Holdings Limited (ATIF) +70% on establishing SPAC department to plan establishment of SPAC.Xcel Brands (XELB) +52%.Celsion Corporation (CLSN) +48% after receiving FDA fast track designation for GEN-1.Can-Fite BioPharma (CANF) +28% on p...
-
VBL Therapeutics (VBLT) gains 16% premarket after the independent Data Safety Monitoring Committee ((DSMC)) announces review of OVAL Phase 3 study of VB-111 in recurrent ovarian cancer.The committee found no safety issues with the trial and recommended its continuation as planned. N...
-
TEL AVIV, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer. The co...
-
VBL Therapeutics (VBLT) has dosed the first patient in a randomized controlled Phase 2 study evaluating VB-201 for the treatment of COVID-19. The study will assess the ability of VB-201 to prevent clinical deterioration and reduce morbidity and mortality in patients with severe COVID-19.Studi...
-
TEL AVIV, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-...
-
Palm Beach, FL – January 25, 2021 Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been r...
-
Adamis Pharmaceuticals (ADMP) +66% as its epinephrine products added to Walgreens club.Climate Change Crisis Real Impact I Acquisition Corporation (CLII) +48% as EV fast charging company EVgo to go public via SPAC.SCYNEXIS (SCYX) +36%.Humanigen (HGEN) +20% on expanding partners...
-
VBL Therapeutics (VBLT) has entered into share purchase agreements with Aspire Capital Fund, under which Aspire has committed to buying up to $20M of the company's common stock over a 30-month period.Proceeds from sales of ordinary shares pursuant to the purchase agreement will be u...
Stock Information
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
MENU
VBLT
VBLT Quote
VBLT Short
VBLT News
VBLT Articles
Get VBLT Alerts
News, Short Squeeze, Breakout and More Instantly...
-
TEL AVIV, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer. The co...
-
TEL AVIV, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-...
-
TEL AVIV, Israel, Jan. 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications, tod...